Hikma Pharmaceuticals (HIK) Price & Analysis

Compare

74 Followers

HIK Stock Chart & Stats

Day’s Range― - ―

52-Week Range1,578.00p - 2,360.00p

Previous CloseN/A

Volume7.28K

Average Volume (3M)644.84K

Market Cap

£3.96B

Enterprise Value5.40B

Total Cash (Recent Filing)£236.00M

Total Debt (Recent Filing)£1.55B

Price to Earnings (P/E)13.1

Beta0.79

Next Earnings

Feb 19, 2026

EPS EstimateN/A

Last Dividend Ex-Date

Aug 14, 2025

Dividend Yield3.47%

Share Statistics

EPS (TTM)0.91

Shares Outstanding221,886,460

10 Day Avg. Volume721,039

30 Day Avg. Volume644,843

Financial Highlights & Ratios

PEG Ratio0.17

Price to Book (P/B)2.41

Price to Sales (P/S)1.78

P/FCF Ratio13.93

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

£2,506.40

Price Target Upside36.74% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

Bulls Say, Bears Say

Bulls Say

Investment OpportunityA market overreaction has created an opportunity for investors, as recent macro tariff news has inappropriately affected Hikma, exposing both short- and long-term opportunity.

Market DemandStrong demand in European and MENA markets, while North America benefitting from good demand for the recently launched liraglutide injection and the contribution from the newly acquired Xellia portfolio.

Strategic PositioningHikma is well positioned with market tariff concerns due to a strong US manufacturing presence and limited import exposure.

Bears Say

Revenue Growth ChallengesCompany continues to expect 7-9% FY25 revenue growth, with phasing and mix of sales expected to impact margins in 1H, but FY25 core operating margin maintained in the mid-30s.

Hikma Pharmaceuticals News

Hikma Pharmaceuticals Executives Acquire Shares, Signaling Confidence

The latest update is out from Hikma Pharmaceuticals ( ($GB:HIK) ). Hikma Pharmaceuticals PLC announced that several of...

11d ago

Hikma Pharmaceuticals Executive Vice Chairman Acquires Shares

The latest update is out from Hikma Pharmaceuticals ( ($GB:HIK) ). Hikma Pharmaceuticals announced a transaction involving Mazen...

17d ago

Hikma Pharmaceuticals Director Acquires Shares, Signaling Confidence

Hikma Pharmaceuticals ( ($GB:HIK) ) has provided an announcement. Hikma Pharmaceuticals announced a transaction involving Laura Balan, a...

1M ago

Hikma Pharmaceuticals Executive Exercises Share Options

An update from Hikma Pharmaceuticals ( ($GB:HIK) ) is now available. Hikma Pharmaceuticals announced that Susan Ringdal, a...

2M ago

Hikma Pharmaceuticals’ Earnings Call: Mixed Financial Performance

Hikma Pharmaceuticals (($GB:HIK)) has held its Q2 earnings call. Read on for the main highlights of the call....

2M ago

Hikma Pharmaceuticals Executive Vice Chairman Acquires Significant Shareholding

The latest announcement is out from Hikma Pharmaceuticals ( ($GB:HIK) ). Hikma Pharmaceuticals announced a significant transaction involving...

2M ago

Hikma Pharmaceuticals Reports Strong H1 2025 Performance and Positive Outlook

An update from Hikma Pharmaceuticals ( ($GB:HIK) ) is now available. Hikma Pharmaceuticals reported solid performance in the...

2M ago

Hikma Pharmaceuticals Issues $500 Million in Guaranteed Notes

The latest update is out from Hikma Pharmaceuticals ( ($GB:HIK) ). Hikma Pharmaceuticals, through its subsidiary Hikma Finance...

3M ago

Hikma Pharmaceuticals Discloses Managerial Share Disposal

Hikma Pharmaceuticals ( ($GB:HIK) ) has provided an announcement. Hikma Pharmaceuticals announced a transaction involving the disposal of...

4M ago

Hikma Pharmaceuticals Discloses Share Disposal by Key Executive

Hikma Pharmaceuticals ( ($GB:HIK) ) has provided an update. Hikma Pharmaceuticals announced a transaction involving the disposal of...

4M ago

HIK FAQ

What was Hikma Pharmaceuticals PLC’s price range in the past 12 months?

Hikma Pharmaceuticals PLC lowest share price was 1578.00p and its highest was 2360.00p in the past 12 months.

What is Hikma Pharmaceuticals PLC’s market cap?

Hikma Pharmaceuticals PLC’s market cap is £3.96B.

When is Hikma Pharmaceuticals PLC’s upcoming earnings report date?

Hikma Pharmaceuticals PLC’s upcoming earnings report date is Feb 19, 2026 which is in 138 days.

How were Hikma Pharmaceuticals PLC’s earnings last quarter?

Hikma Pharmaceuticals PLC released its earnings results on Aug 07, 2025. The company reported 0.908p earnings per share for the quarter, the consensus estimate of 0.908p by 0p.

Is Hikma Pharmaceuticals PLC overvalued?

According to Wall Street analysts Hikma Pharmaceuticals PLC’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Hikma Pharmaceuticals PLC pay dividends?

Hikma Pharmaceuticals PLC pays a Semiannually dividend of 26.556p which represents an annual dividend yield of 3.47%. See more information on Hikma Pharmaceuticals PLC dividends here

What is Hikma Pharmaceuticals PLC’s EPS estimate?

Hikma Pharmaceuticals PLC’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Hikma Pharmaceuticals PLC have?

Hikma Pharmaceuticals PLC has 221,886,460 shares outstanding.

What happened to Hikma Pharmaceuticals PLC’s price movement after its last earnings report?

Hikma Pharmaceuticals PLC reported an EPS of 0.908p in its last earnings report, expectations of 0.908p. Following the earnings report the stock price went down -7.112%.

Which hedge fund is a major shareholder of Hikma Pharmaceuticals PLC?

Currently, no hedge funds are holding shares in GB:HIK

Hikma Pharmaceuticals Stock Smart Score

Outperform

Fundamentals

Return on Equity

15.66%

Trailing 12-Months

Asset Growth

5.70%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Hikma Pharmaceuticals PLC

Hikma Pharmaceuticals PLC is a global pharmaceutical company headquartered in London, UK, that specializes in the development, manufacturing, and marketing of a broad range of generic and branded medications. The company operates primarily through two main business segments: Injectables and Generics, as well as a growing portfolio of branded products. Hikma’s core offerings include injectable medications, oral solids, and specialty pharmaceuticals, with a focus on therapeutic areas such as oncology, cardiovascular, and pain management.

Hikma Pharmaceuticals (HIK) Earnings & Revenues

Historic Earnings Reports

HIK Stock 12 Month Forecast

Average Price Target

2,506.40p

▲(36.74% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1811":"1,811p","2071":"2,071p","2331":"2,331p","2591":"2,591p","2851":"2,851p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2850,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">2.85K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2506.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">2.51K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1982,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">1.98K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1811,2071,2331,2591,2851],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1910.57,1982.833846153846,2055.0976923076923,2127.3615384615387,2199.6253846153845,2271.889230769231,2344.1530769230767,2416.416923076923,2488.6807692307693,2560.9446153846156,2633.2084615384615,2705.472307692308,2777.7361538461537,{"y":2850,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1910.57,1956.403076923077,2002.236153846154,2048.0692307692307,2093.9023076923077,2139.7353846153846,2185.5684615384616,2231.4015384615386,2277.2346153846156,2323.0676923076926,2368.900769230769,2414.733846153846,2460.566923076923,{"y":2506.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1910.57,1916.0646153846153,1921.5592307692307,1927.053846153846,1932.5484615384614,1938.0430769230768,1943.5376923076922,1949.0323076923078,1954.5269230769231,1960.0215384615385,1965.5161538461539,1971.0107692307693,1976.5053846153846,{"y":1982,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1816.91,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1910.45,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1849.48,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1812.7,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1871.74,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1928.84,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2218.22,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2090.47,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1919.44,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1969.69,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2116.5,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1962.79,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1910.57,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >